Charles Vauchier
University of Paris
Lung cancerImmunotherapyPOLD1Microsatellite instabilityPembrolizumabDNA polymerase epsilonMismatch Repair PathwayCancer researchDNA mismatch repairMedicine
Publications 1
#1Charles Vauchier (University of Paris)
#2Johan Pluvy (University of Paris)H-Index: 1
Last. Gérard Zalcman (Curie Institute)H-Index: 9
view all 8 authors...
Immunotherapy with immune checkpoint inhibitors (ICIs) represents a major breakthrough in lung cancer treatment. For patients with advanced non-small-cell lung cancer (NSCLC) and poor performance status (PS), the availability of sensitivity markers to immune-checkpoint inhibitors (ICI) would be useful for attending physicians and assist them in their decision-making process. Deficient mismatch repair (dMMR) can lead to high microsatellite instability (MSI-H) and coexist with mutations in polymer...